



# Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.





## NeoTYPE® Precision Profile for Solid Tumors

### Alternative Name

Solid Tumor Profile, Precision Profile

### Methodology

Molecular

### Test Description

The NeoTYPE Precision Profile analyzes 83 biomarkers through a combination of next-generation sequencing (NGS) and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions. If Pan-TRK IHC is expressed or equivocal, reflex to either NTRK NGS Fusion Panel (Default) or NTRK 1-3 FISH Panel will be added. A microsatellite instability (MSI) NGS result of “indeterminate” will create a reflex to MSI by PCR as long as the tumor percentage is ≥20% for colorectal specimens or ≥40% with paired normal tissue available for non-colorectal specimens.

- NGS (79 genes + 2 biomarkers): AKT1, ALK, APC, ARAF, ATM, ATR, BARD1, BRAF, BRCA1, BRCA2, BRIP1, CDH1, CDK12, CDKN2A, CHEK1, CHEK2, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, ESR1, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL, FBXW7, FGFR1, FGFR2, FGFR3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, KDR, KIT, KRAS (includes G12C mutation), MAP2K1, MET, Microsatellite Instability (MSI), MLH1, MSH2, MSH6, MRE11A (MRE11), MTOR, NBN, NF1, NOTCH1, NRAS, PALB2, PDGFRA, PIK3CA, PMS2, PTCH1, PTEN, PTPN11, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TSC1, TSC2, TERT Promoter, TP53, Tumor Mutation Burden (TMB), VHL
- IHC (2 biomarkers): PD-L1 LDT, Pan-TRK (tech-only available for PD-L1)

### Clinical Significance

Molecular profiling with the NeoTYPE™ Precision Profile for Solid Tumors allows for the accurate and sensitive detection of somatic mutations in the genes most relevant to various solid tumor cancers. Testing can aid in the diagnosis of various diseases and provide information to develop strategies for the treatment and management of the underlying disease. In addition, the results obtained from the NeoTYPE™ Precision Profile for Solid Tumors can also be used in current or future clinical research projects.

### Specimen Requirements

- **FFPE solid tumor tissue:** Paraffin block is preferred. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.

### Storage & Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

### CPT Code(s)\*

81455x1, 88360x1, 88342x1; add 81479x1 if reflexed to NTRK NGS Fusion Panel (default) or 88374x3 automated (88377x3 manual) if reflexed to NTRK 1-3 FISH Panel

### Medicare MoIDX CPT Code(s)\*

81479

**New York Approved**

Yes

**Level of Service**

Global

**Turnaround Time**

14 days

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

\*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.



9490 NeoGenomics Way  
Fort Myers, FL 33912  
Phone: 239.768.0600/ Fax: 239.690.4237  
neogenomics.com  
© 2024 NeoGenomics Laboratories, Inc. All Rights Reserved.  
All other trademarks are the property of their respective owners  
Rev. 052024